http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#Head
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#assertion
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#provenance
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#pubinfo
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#assertion
http://purl.obolibrary.org/obo/DOID_8545
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8545
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01219
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
http://www.w3.org/2000/01/rdf-schema#label
dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders e g spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders if improvement occurs it will ordinarily occur within the dosage titration see dosage and administration occasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsules therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression a decision to continue the administration of dantrolene sodium capsules on a long term basis is justified if introduction of the drug into the patient s regimen produces a significant reduction in painful and or disabling spasticity such as clonus or permits a significant reduction in the intensity and or degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himself oral dantrolene sodium capsules is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia and or surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodium oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#association
https://w3id.org/biolink/vocab/relation
https://schema.org/PreventionIndication
https://identifiers.org/drugbank:DB01219
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#provenance
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#pubinfo
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#sig
http://purl.org/nanopub/x/hasSignature
XK7cfZAibCXYhnFpG5lJjWPCSGg783aSa36/UqK8mOPJzIKcjyICaBkDVNN0rLMleLrpIjcnKB6yAoBtejZJOoMX9RufLkQBiLKE6bAON7iekKsNecEBH70I0xrXUmp6LtNiToXd9n6ku6ovl5l5JLzmoshX3FDyk/3j4ZZuAjk=
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://purl.org/dc/terms/created
2021-06-12T15:32:33.425+02:00
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA8N_evLf_PGjY3A0pKwmr5kkuZhCAH8ZbD8Pm3QNL3J0
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs